Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21937723 | 0.84 | PNMT (0.39) | PNMTSLC6A4SLC6A2SLC6A3TSHR | |
| SCHEMBL25146528 | 0.78 | L3MBTL1 (0.51) | L3MBTL1 | |
| SCHEMBL25146541 | 0.78 | L3MBTL1 (0.51) | L3MBTL1 | |
| SCHEMBL20900769 | 0.77 | PNMT (0.49) | PNMTTSHRRECQLTAAR1SIGMAR1 | |
| SCHEMBL10423175 | 0.75 | SLC6A4 (0.46) | PNMTSLC6A4SLC6A2SLC6A3TAAR1 | |
| SCHEMBL9667972 | 0.75 | SLC6A4 (0.50) | PNMTSLC6A4SLC6A2SLC6A3TAAR1 | |
| SCHEMBL31374947 | 0.75 | SLC6A4 (0.46) | PNMTSLC6A4SLC6A2SLC6A3TAAR1 | |
| SCHEMBL5218251 | 0.71 | PNMT (0.50) | PNMTSLC6A4SLC6A3TAAR1SIGMAR1 | |
| SCHEMBL25518220 | 0.71 | PNMT (0.46) | PNMTSLC6A4SLC6A3TAAR1SIGMAR1 | |
| SCHEMBL25209309 | 0.70 | PNMT (0.48) | PNMTSLC6A4SLC6A2SLC6A3TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | PNMT 2717/4885SLC6A4 1226/4885SLC6A2 914/4885 |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | PNMT 2717/4885SLC6A4 1226/4885SLC6A2 914/4885 |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | PNMT 3116/4885SLC6A4 1541/4885SLC6A2 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.